The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-kappaB inflammatory pathway in the MPTP mouse model of Parkinsons disease more effectively than the GLP-1 single-receptor agonist NLY01
GLP-1 Therapy in Inglewood, CA GLP-1s are safe, doctor-prescribed medications delivered as a small shot under the skin, rotating between the stomach, thighs, and upper arm
Pathophysiological Roles of Intestinal NAD + Biosynthesis The intestine is a central regulator of glucose metabolism [128,129,130]
Increasing or at least maintaining muscle mass through protein intake and weight bearing exercises during a weight loss program will support the maintenance of basal metabolic rate (BMR) and prioritize the loss of fat rather than muscle
The 2025 GLP-1 guidelines have positioned these drugs at the forefront of type 2 diabetes management, reflecting their multifaceted benefits
In a recent NOTW, I shared what I believed to be the three reasons behind the weakness (in relevance order): The narrative around oral GLP-1s Schotts weak FY 2026 guidance (shared early in December) Stevanatos low float (80% or so remains in the hands of the Stevanato family) #3 is what it is and we cant do much about it